ViroCyt Overview

  • Founded
  • 2012
  • Status
  • Acquired/​Merged
  • Employees
  • 11
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $15.4M
Latest Deal Amount

ViroCyt General Information


Developer of rapid quantification technology for viruses. The company provides the tools that deliver biotechnology processes such as vaccine manufacturing, protein expression and antiviral development for vaccine companies, bio-technologies, domestic and foreign government research institutes and universities.

Contact Information

Ownership Status
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Discovery Tools (Healthcare)
Primary Office
  • 100 Technology Drive
  • Suite 325-C
  • Broomfield, CO 80021
  • United States
+1 (720) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

ViroCyt Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 15-Jul-2016 $15.4M 000.00 000.00 Completed Generating Revenue
3. Early Stage VC 29-Apr-2015 000 000.00 Completed Generating Revenue
2. Early Stage VC 09-Jan-2015 $3.47M $11.7M Completed Generating Revenue
1. Early Stage VC (Series B) 10-Apr-2013 $8.2M $8.2M Completed Generating Revenue
To view ViroCyt’s complete valuation and funding history, request access »

ViroCyt Comparisons

HQ Location
Total Raised
Post Valuation
Last Financing Details
Developer of rapid quantification technology for viruses. The company provides the tools that deliver biotechnology proc
Broomfield, CO
11 As of 2016
00.00 0000-00-00
000000&0 000.00


ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse c
Beit-Haemek, Israel
000 As of 0000
00.00 0000-00-00
000000&0 0000


s aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Boulder, CO
00 As of 0000
000000000 - 000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ViroCyt Competitors (11)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Biological Industries Formerly PE-Backed Beit-Haemek, Israel 000 0000 000000&0 0000
000000 Venture Capital-Backed Boulder, CO 00 000 000000000 - 000
000000000 00000000 Private Equity-Backed Mississauga, Canada 000 0000 000000 - 000 0000
0000000 000 Formerly PE-Backed Cambridge, MA 000 000000&0
00000000 000 Formerly VC-backed Cambridge, MA 0000 00000 00000000 00000
You’re viewing 5 of 11 competitors. Get the full list »

ViroCyt Executive Team (6)

Name Title Board Seat Contact Info
Greg Krueger Vice President, Global Sales
Michael Artinger Ph.D Vice President, Marketing & Strategic Partnering
Michael Olszowy Ph.D Chief Technology Officer
You’re viewing 3 of 6 executive team members. Get the full list »

ViroCyt Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ViroCyt Former Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
High Country Venture Venture Capital Minority 000 0000 000000 0
InDevR VC-Backed Company Majority 000 0000 000000 0
Jennifer Baird Angel (individual) Minority 000 0000 000000 0
To view ViroCyt’s complete investors history, request access »